D-cylcoserine phosphate in complex with ADP and magnesium bound at the active site of E. coli D-ala-D-alanine ligase. Courtesy of University of Warwick
Led by professor David Roper at the University of Warwick's School of Life Sciences and Dr Luiz Pedro Carvalho from the Francis Crick Institute, a paper published today in Nature Communications reveals a deeper understanding of how the antibiotic D-cycloserine uniquely works at a molecular level.
This could lead to more effective future antibiotics, which are desperately needed to fight increasingly drug-resistant and deadly bacteria.
D-cycloserine is an old antibiotic drug which is effective against many microbial diseases such as tuberculosis, but is often used as a second line treatment, because of some adverse side-effects.
The researchers have now discovered that it acts chemically in very different ways on multiple bacterial targets - possibly the only antibiotic in the world to do so.
The drug attacks bacteria by inhibiting two separate enzymes (D-alanine racemase and D-alanine--D-alanine ligase) each required to build and maintain the structural integrity of bacterial cell walls.
With the D-alanine racemase enzyme, it is known that the drug forms a molecular bond with a chemical group required for the enzyme activity, stopping it from working.
The researchers have observed, for the first time, how D-cycloserine inhibits the D-alanine-D-alanine ligase enzyme.
David Roper, who is professor of biochemistry and structural biology at the University Warwick, commented, "In this new discovery, we see that D-cycloserine binds to the D-alanine-D-alanine ligase enzyme and becomes chemically modified on the enzyme. The chemical species formed here has never been seen before. We now understand fully how this antibiotic drug can have totally different methods of working on separate targets. This appears to be a unique amongst the antibiotics."
Dr, Luiz Pedro Carvalho, from the Mycobacterial Metabolism and Antibiotic Research Laboratory at the Francis Crick Institute, said, "Perhaps more important than how D-cycloserine works, this study highlights an increasingly obvious fact: we know much less than we think about how antibiotics really work and how bacteria become resistant. Only by truly understanding molecular and cellular events caused by antibiotics or in response to their presence will we truly understand how to make improved drugs, which are much needed in face of the current threat of antibiotic resistance."
A longer term goal will be to modify the structure of D-cycloserine, so that it more closely resembles the newly discovered chemical species, and in so doing produce an antibiotic that is more specific and avoids some of adverse side effects of D-cycloserine - enabling its wider use in the fight against antibiotic resistant infections.
There is a global crisis in healthcare because bacterial infections are becoming increasingly resistant to the antibiotic drugs we use to treat them. Antimicrobial resistance threatens many aspects of human activity including medicine and agriculture and could lead to more deaths than cancer.
The research, 'Inhibition of D-Ala:D-Ala ligase through a novel phosphorylated antibiotic', is published in Nature Communications.
Source: University of Warwick
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.